Skip to content

Treasury Stock at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$0

Other financials

Income statement

See full
Revenue$168.3M-9.8%
Gross profit$118.7M-10.7%
Operating income-$30.4M-50.7%
Net income-$52.0M+28.4%
EPS (diluted)-$5.20-471%

Balance sheet

See full
Cash & equivalents$120.9M-48.9%
Total debt$468.2M-71.7%
Total equity$265.6M+122%
Total assets$881.1M+26.4%

Cash flow

See full
Operating cash flow-$33.5M-324%
CapEx$6.0K
Free cash flow$8.4M

Valuation

See full
Market cap$159.78M-95.6%
Enterprise value$507.1M-87.2%
P/S0.3×+0.2×

Profitability

See full
Gross margin71%+5.5pp
Operating margin-34.5%-37.5pp
Net margin-23.2%-8.6pp
FCF margin-0.7%-3.3pp

Returns & leverage

See full
Return on equity268.4%
Debt / equity1.8×
Current ratio1.2×+1.0×

Where this comes from

Reported directly by WW International, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The official record: WW International, Inc.’s 10-Q, filed August 11, 2025, on SEC EDGAR. View the filing →

Ask your AI about WW International, Inc.'s treasury stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WW International, Inc.'s treasury stock?
WW International, Inc. (WW) reported treasury stock of $0 in Q2 2025.
How has WW International, Inc.'s treasury stock changed year-over-year?
WW International, Inc.'s treasury stock decreased by 100.0% year-over-year, from $3.04B to $0.
What is the long-term trend for WW International, Inc.'s treasury stock?
Over 4 years (2020 to 2024), WW International, Inc.'s treasury stock has grown at a -0.9% compound annual growth rate (CAGR), from $3.14B to $3.02B.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.